Monitoring of radiochemotherapy in patients with glioblastoma using O-(2-[18F]fluoroethyl)-L-tyrosine positron emission tomography: Is dynamic imaging helpful?

Molecular Imaging

Volumn 12, Issue 6, 2013, Pages

  Piroth, Marc D ^a,b,c,d   Liebenstund, Sarah ^a,b,c,d   Galldiks, Norbert ^a,b,c,d   Stoffels, Gabriele ^a,b,c,d   Shah, Nadim J ^a,b,c,d   Eble, Michael J ^a,b,c,d   Coenen, Heinz H ^a,b,c,d   Langen, Karl Josef ^a,b,c,d  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b FORSCHUNGSZENTRUM JÜLICH   (Germany)

^c UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^d Julich Aachen Research Alliance JARA   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST ENHANCEMENT; KINETIC BEHAVIOR; POSITRON EMISSION TOMOGRAPHY (PET); PREDICTIVE VALUES; RADIOCHEMOTHERAPY; TIME-ACTIVITY CURVES; TUMOR METABOLISMS; TUMOR PROGRESSIONS;

AMINO ACIDS; BREEDER REACTORS; CHEMORADIOTHERAPY; MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY;

TUMORS;

EID: 84883409854     PISSN: 15353508     EISSN: None     Source Type: Journal    
DOI: 10.2310/7290.2013.00056     Document Type: Article

References (21)

1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96, doi:10.1056/NEJMoa043330.
2. Kumar AJ, Leeds NE, Fuller GN, et al. Malignant gliomas: MR imaging spectrum of radiation therapy- and chemotherapyinduced necrosis of the brain after treatment. Radiology 2000; 217:377-84.
3. Herholz K, Langen KJ, Schiepers C, Mountz JM. Brain tumors. Semin Nucl Med 2012;42:356-70, doi:10.1053/j.semnuclmed.2012.06.001.
4. Langen KJ, Bartenstein P, Boecker H, et al. German guidelines for brain tumour imaging by PET and SPECT using labelled amino acids. Nuklearmedizin 2011;50:167-73, doi:10.3413/nuk-2011041.
5. Langen KJ, Hamacher K, Weckesser M, et al. O-(2- [18F]fluoroethyl)-L- tyrosine: uptake mechanisms and clinical applications. Nucl Med Biol 2006;33:287-94, doi:10.1016/j.nucmedbio.2006.01.002.
6. Langen KJ, Tatsch K, Grosu AL, et al. Diagnostics of cerebral gliomas with radiolabeled amino acids. Dtsch Arztebl Int 2008;105: 55-61.
7. Pauleit D, Floeth F, Hamacher K, et al. O-(2-[18F]fluoroethyl)-Ltyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas. Brain 2005;128:678-87, doi:10. 1093/brain/awh399.
8. Pauleit D, Stoffels G, Bachofner A, et al. Comparison of (18)F-FET and (18)F-FDG PET in brain tumors. Nucl Med Biol 2009;36:779-87, doi:10.1016/j.nucmedbio.2009.05.005.
9. Pöpperl G, Götz C, Rachinger W, et al. Value of O-(2- [18F]fluoroethyl)-L-tyrosine PET for the diagnosis of recurrent glioma. Eur J Nucl Med Mol Imaging 2004;31:1464-70, doi:10.1007/s00259-004-1590-1.
10. Galldiks N, Langen K, Holy R, et al. Assessment of treatment response in patients with glioblastoma using [18F]fluoroethyl-Ltyrosine PET in comparison to MRI. J Nucl Med 2012;53:1048-57, doi:10.2967/jnumed.111.098590.
11. Piroth MD, Pinkawa M, Holy R, et al. Prognostic value of early [18F]fluoroethyltyrosine positron emission tomography after radiochemotherapy in glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2011;80:176-84, doi:10.1016/j.ijrobp.2010.01.055.
12. Galldiks N, Stoffels G, Filss CP, et al. Role of O-(2-18Ffluoroethyl)-L- tyrosine PET for differentiation of local recurrent brain metastasis from radiation necrosis. J Nucl Med 2012;53: 1367-74, doi:10.2967/jnumed.112.103325.
13. Kunz M, Thon N, Eigenbrod S, et al. Hot spots in dynamic (18)FET-PET delineate malignant tumor parts within suspected WHO grade II gliomas. Neuro-oncology 2011;13:307-16.
14. Pöpperl G, Kreth FW, Mehrkens JH, et al. FET PET for the evaluation of untreated gliomas: correlation of FET uptake and uptake kinetics with tumour grading. Eur J Nucl Med Mol Imaging 2007;34:1933-42, doi:10.1007/s00259-007- 0534-y.
15. Weckesser M, Langen KJ, Rickert CH, et al. O-(2-[18F]fluorethyl)- L-tyrosine PET in the clinical evaluation of primary brain tumours. Eur J Nucl Med Mol Imaging 2005;32:422-9, doi:10.1007/s00259-004-1705-8.
16. Piroth MD, Pinkawa M, Holy R, et al. Integrated boost IMRT with FET-PET-adapted local dose escalation in glioblastomas. Results of a prospective phase II study. Strahlenther Onkol 2012;188:334-9, doi:10.1007/s00066-011-0060- 5.
17. Hamacher K, Coenen HH. Efficient routine production of the 18Flabelled amino acid O-2-18F fluoroethyl-L-tyrosine. Appl Radiat Isot 2002;57:853-6, doi:10.1016/S0969-8043(02)00225-7.
18. Vollmar S, Hampl J, Kracht L, Herholz K. Integration of functional data (PET) into brain surgery planning und neuronavigation. Springer Proc Phys 2007;114:98-103, doi:10.1007/978-3-540-68764-1-16.
19. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990;8:1277-80.
20. Thiele F, Ehmer J, Piroth MD, et al. The quantification of dynamic FET PET imaging and correlation with the clinical outcome in patients with glioblastoma. Phys Med Biol 2009;54:5525-39, doi:10.1088/0031-9155/54/18/012.
21. Galldiks N, Rapp M, Stoffels G, et al. Response assessment of bevacizumab in patients with recurrent malignant glioma using [(18)F]fluoroethyl-L-tyrosine PET in comparison toMRI. Eur J Nucl Med Mol Imaging 2013;40:22-33, doi:10.1007/s00259-012-2251-4.